非小细胞肺癌腹膜转移研究进展  

Advances in the studies on the peritoneal carcinomatosis of non-small cell lung cancer

作　　者：郑琪[1] 赵征[1] 廖子君[1] 李索妮[1] 白杰[1] 李倩[1] Zheng Qi;Zhao Zheng;Liao Zijun;Li Suoni;Bai Jie;Li Qian(Department of Medical Oncology,Affiliated Shaanxi Provincial Tumor Hospital,College of Medicine,Xi'an Jiaotong University,Xi'an 71006l,China)

机构地区：[1]西安交通大学医学院附属陕西省肿瘤医院肿瘤内科,西安710061

出　　处：《中国肿瘤临床与康复》2023年第5期315-320,共6页Chinese Journal of Clinical Oncology and Rehabilitation

基　　金：陕西省自然科学基础研究计划资助项目(2021JM-582)。

摘　　要：非小细胞肺癌(NSCLC)腹膜转移在临床上较为罕见,发病机制尚未阐明.腹膜转移多见于肺腺癌患者,常继发于其他脏器转移或恶性胸腔积液之后发生,临床上表现为腹水、肠梗阻等症状,病情发展迅速,预后较差.腹膜转移的诊断主要依据临床症状、影像学检查、腹水脱落细胞学或腹膜活检病理结果.腹膜转移的治疗,主要依据晚期NSCLC治疗指南,部分患者可能通过包含手术、化疗、分子靶向治疗、免疫检查点抑制剂等系统治疗获益,预后得到改善.Peritoneal carcinomatosis(PC)of non-small cell lung cancer(NSCLC)is infrequently seen in clinical practice,and the mechanisms are not clarified until now.PCs are often observed in lung adenocarcinoma patients,and are always secondary to visceral metastases or malignant pleural effusion.PCs are often presented with symptoms of ascites or intestinalobstruction,which leads to rapid progression and poor prognosis.PC of NSCLC are diagnosed based on clinical symptoms,radiological examinations,pathological examinations on ascites cytology or peritoneal biopsy.NSCLC treatment guildlinesare the main references to treat PC.A few patients may benefit from comprehensive treatments including operation,chemotherapy,molecular targeted therapy,immune checkpoint inhibitor and so on,and obtain improved prognoses.

关 键 词：非小细胞肺癌 腹膜转移 分子靶向治疗 免疫检查点抑制剂 预后 

分 类 号：R734.2[医药卫生—肿瘤]